Replimune Group, Inc. (REPL) Stock Price & Analysis

Replimune Group, Inc. (REPL) closed at USD 16.06 on Wednesday, October 28, 2026, up 23.07% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 13.05; the Oct 28, 2026 session ranged USD 12.5–16.75 on volume of 7,277,843 shares. Market capitalization is $1.51B, with a 52-week range of USD 1.5–16.75 (NMS). Source: Nexqual, retrieved October 28, 2026 at 21:41 UTC.

Also available as compact Markdown for AI agents: nexqual.com/REPL.md

Key facts (REPL)

• Insider open-market sales, last ~7 months: 12 Form 4 filings, $1.6M; 11 not under a Rule 10b5-1 plan ($1.5M); 0 by opportunistic insiders, 7 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.00 on a 1–5 scale) (8 analysts), mean target USD 19.5 (range 14–24).
• Total return with dividends: 1Y +57.3% vs S&P 500 +13.6%; 5Y -45.6% vs S&P 500 +79.8%.
• Next earnings: 2026-10-28, EPS estimate USD -0.76, revenue estimate $6.7M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (REPL)

Fiscal years end Mar. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (REPL)

P/B 14.3x · FCF yield -18.54% · Earnings yield -19.63% · Net cash $111M · EV $1.40B

Insider sales (SEC Form 4, open-market, last ~7 months) (REPL)

1 of 12 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (REPL)

Consensus Buy (mean 2.00 on a 1–5 scale), 8 analysts; mean target USD 19.5 (low 14, high 24).

Rating changes, last 120 days:

Total return (dividends reinvested) (REPL)

REPL earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

REPL recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

REPL suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Jun 29, 2026.

REPL analyst estimates and revisions

REPL options: expected move

Options price a move of about ±11.6% (±$1.53) by Oct 30, 2026, which includes earnings on Oct 28, 2026. Over the last 8 reports the stock moved ±4.4% on average.

30-day implied volatility 90.9% vs 84.4% realized over the last 30 trading days. Put/call ratio (volume) 0.55. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 28, 2026 at 21:41 UTC)

Technical Analysis (REPL)

Nexqual's technical model rates REPL "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 28, 2026 at 21:41 UTC.

Analyst Ratings (REPL)

Wall Street analysts rate REPL "Buy" based on 8 analysts, with a mean price target of USD 19.5 (range USD 14–24), per Nexqual as of October 28, 2026 at 21:41 UTC.

Earnings (REPL)

Recent Earnings History

Source: Nexqual, October 28, 2026 at 21:41 UTC.

Financials & Fundamentals (REPL)

Source: Nexqual, October 28, 2026 at 21:41 UTC.

Financial Health Score (REPL)

Nexqual rates Replimune Group, Inc.'s overall financial health "Weak" across five dimensions, as of October 28, 2026 at 21:41 UTC.

Ownership (REPL)

Source: Nexqual, October 28, 2026 at 21:41 UTC.

Leadership (REPL)

Replimune Group, Inc. is led by Sushil Patel, CEO & Director, per Nexqual as of October 28, 2026 at 21:41 UTC.

Major Backers & Investors (REPL)

Notable institutional backers of Replimune Group, Inc. include Baker Bros. Advisors, LP, RTW Investments LP, Ridgeback Capital Investments L.P., according to Nexqual as of October 28, 2026 at 21:41 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 28, 2026 at 21:41 UTC.

From Replimune Group, Inc.'s Latest SEC 10-K Filing (filed 2026-06-29)

Key Strengths & Strategy (as disclosed to the SEC)

• We seek to protect our proprietary technology and processes, in part, by confidentiality agreements with our employees, consultants, scientific advisors and other contractors, as well as physical security of our premises and our information technology systems. management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business.
• In the United States, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public Health Services Act, or PHSA, and their implementing regulations.
• Our proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer.
• Our proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.

Partnerships

• In April 2019, we entered into a separate agreement with BMS on terms similar to the terms set forth in the agreement described above, pursuant to which BMS will provide, at no cost to us, nivolumab for use in our Phase 1 clinical trial of RP2 in combination with nivolumab.
• We continue our signal finding trial of RP2 in combination with atezolizumab and bevacizumab in the 2L setting of patients with hepatocellular carcinoma, or HCC, in collaboration with Roche.

Legal & Regulatory Risks (Item 1A, quoted)

• We are not permitted to market or promote or sell any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates.
• Our ability to market, sell, distribute, obtain acceptable reimbursement for, set pricing for, and continue to operate and develop RP1 may be further delayed, adversely affected or prevented altogether.
• The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain, or experience delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates as expected, and our ability to generate revenue may be materially impaired.
• The FDA or a comparable foreign regulatory authority may determine that our product candidates have undesirable side effects that could delay or prevent their regulatory approval or commercialization.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 21:41 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt